FDA approves Kisunla, the second drug to slow Alzheimer’s, offering a new option for early-stage patients.
FDA approves second drug to slow Alzheimer’s progression | Benefits and Pensions Monitor
About the Author:
FDA approves Kisunla, the second drug to slow Alzheimer’s, offering a new option for early-stage patients.
Leave A Comment